Madrigal Pharmaceuticals Inc (MDGL) FinancialsMDGLFinancialMadrigal Pharmaceuticals Inc

Evaluating the bottom line, Madrigal Pharmaceuticals, Inc. maintains a gross margin of 89.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.46%, while the net margin is -15.91%. These profitability ratios, combined with a Return on Equity (ROE) of -53.31%, provide a clear picture of how effectively MDGL converts its operational activities into shareholder value.

In the context of the broader market, MDGL competes directly with industry leaders such as CORT and AAPG. With a market capitalization of $12.45B, it holds a leading position in the sector. When comparing efficiency, MDGL's gross margin of 89.02% stands against CORT's 98.41% and AAPG's 96.12%. Such benchmarking helps identify whether Madrigal Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Madrigal's total revenue for Q2 2026 was $364.3 million, and it has shown consistent revenue growth, with a gross margin of 89.02%. However, it has negative net income, with a net margin of -15.91% in Q2 2026.